Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation
Conclusions:
Edoxaban is a welcome addition to the NOAC's armamentarium. However, the comparative data with other novel NOACs are mostly nonexisting, and urgently needed for better individual patient assessment.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Reviews Source Type: research
More News: Anemia | Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Databases & Libraries | Drugs & Pharmacology | Gastroenterology | Genetics | Heart | Pradaxa | Stroke | Study | Warfarin